Point72 Asset Management
KRYS icon

Point72 Asset Management’s Krystal Biotech KRYS Stock Holding History

Point72 Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,299
Closed -$1.9M – 2415
2023
Q4 		$1.9M Sell
15,299
-682,859
-98% -$75.7M ﹤0.01% 1226
2023
Q3 		$81M Buy
698,158
+138,897
+25% +$16.9M 0.24% 84
2023
Q2 		$65.7M Buy
559,261
+56,861
+11% +$5.81M 0.2% 135
2023
Q1 		$40.2M Sell
502,400
-53,852
-10% -$4.23M 0.12% 203
2022
Q4 		$44.1M Sell
556,252
-702,253
-56% -$52.1M 0.15% 181
2022
Q3 		$87.7M Sell
1,258,505
-315,770
-20% -$22.8M 0.35% 59
2022
Q2 		$103M Sell
1,574,275
-145,992
-8% -$9.08M 0.44% 39
2022
Q1 		$114M Sell
1,720,267
-135,889
-7% -$8.48M 0.45% 34
2021
Q4 		$130M Buy
1,856,156
+1,321,456
+247% +$76.9M 0.52% 21
2021
Q3 		$27.9M Buy
534,700
+193,800
+57% +$11.5M 0.12% 221
2021
Q2 		$23.2M Buy
340,900
+171,900
+102% +$12M 0.1% 250
2021
Q1 		$13M Sell
169,000
-331,000
-66% -$24.1M 0.06% 367
2020
Q4 		$30M Sell
500,000
-163,889
-25% -$8.18M 0.15% 191
2020
Q3 		$28.6M Buy
663,889
+124,647
+23% +$5.41M 0.15% 200
2020
Q2 		$22.3M Buy
+539,242
New +$25.9M 0.15% 194
2019
Q3 		– Sell
-101,700
Closed -$4.09M – 1323
2019
Q2 		$4.09M Buy
101,700
+17,616
+21% +$576K 0.02% 551
2019
Q1 		$2.77M Buy
+84,084
New +$1.98M 0.01% 665

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Asset Management's KRYS Position: Q1 2024 in Review

Point72 Asset Management sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 15,299 shares — an estimated $1.9M sold.

Point72 Asset Management first reported a position in KRYS in Q1 2019 and held it in 17 quarters. The position peaked at $130M in Q4 2021. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

  • Point72 Asset Management reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
  • Point72 Asset Management sold 15,299 Krystal Biotech shares in Q1 2024, an estimated $1.9M.
  • Point72 Asset Management first reported a position in Krystal Biotech in Q1 2019 and held it in 17 quarters.
  • Point72 Asset Management's Krystal Biotech position peaked at $130M in Q4 2021.
  • 234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.